Eli Lilly and Company plans to invest $72 million in an insulin-manufacturing project at one of its facilities in Indianapolis, Indiana. The project is part of the company’s $850-million investment in US capital projects, which Lilly announced in March 2017.

The investment will be used to replace an existing insulin vial-filling line for a new one that aligns with modern design expectations and technology, according to Lilly. Insulin is a core element of Lilly’s diabetes business. Humalog (insulin lispro injection), an insulin injection, was Lilly’s top-selling drug in 2016 with global sales of $2.8 billion. The new investment will be used to meet demand for Humalog (insulin lispro) and Humulin (human insulin) and its insulin pipeline.

Lilly has invested more than $1.2 billion since 2012 to boost its US diabetes product manufacturing operations. More broadly, the company has invested $5 billion in its US facilities over the last decade. 

Source: Eli Lilly and Company